Indication
Prostate Small Cell Neuroendocrine Carcinoma
3 clinical trials
6 products
3 drugs
Clinical trial
Radiation Enhancement of Local and Systemic Anti-Prostate Cancer Immune ResponsesStatus: Terminated, Estimated PCD: 2022-09-01
Product
Antiandrogen TherapyProduct
PrednisoneClinical trial
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-19
Product
BerzosertibProduct
TopotecanClinical trial
A Phase I Safety and Feasibility Study of Cellular Immunotherapy for Extensive Stage Small Cell Neuroendocrine Prostate Cancer Using Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen ReceptorStatus: Not yet recruiting, Estimated PCD: 2028-03-15
Product
BendamustineDrug
cyclophosphamideDrug
fludarabine